(Q54030002)
Statements
Phase I clinical evaluation of a new iron oxide MR contrast agent. (English)
S J McLachlan
M R Morris
M A Lucas
R A Fisco
M N Eakins
D R Fowler
R B Scheetz
A Y Olukotun
1 May 1994
4
3
301-307